enGene Holdings Inc. (NASDAQ:ENGN) Short Interest Up 206.2% in February

enGene Holdings Inc. (NASDAQ:ENGN) saw a large increase in short interest in February. As of February 15th, there was short interest totalling 88,500 shares, an increase of 206.2% from the January 31st total of 28,900 shares. Based on an average daily volume of 153,300 shares, the short-interest ratio is presently 0.6 days. Currently, 0.4% of the shares of the stock are short sold.

Analysts Set New Price Targets

A number of analysts have weighed in on ENGN shares. Piper Sandler initiated coverage on shares of enGene in a research note on Tuesday, February 18th. They set an “overweight” rating and a $26.00 target price on the stock. HC Wainwright initiated coverage on enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 price target on the stock. Citizens Jmp raised shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. Raymond James assumed coverage on shares of enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price target for the company. Finally, JMP Securities reissued a “market outperform” rating and issued a $18.00 price objective on shares of enGene in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, enGene currently has an average rating of “Buy” and an average price target of $25.89.

Institutional Trading of enGene

Large investors have recently made changes to their positions in the company. Wolverine Asset Management LLC bought a new position in enGene in the third quarter worth approximately $37,000. Vontobel Holding Ltd. acquired a new position in shares of enGene during the fourth quarter worth approximately $69,000. Jane Street Group LLC bought a new position in shares of enGene in the 4th quarter worth $93,000. Toronto Dominion Bank acquired a new stake in enGene in the 4th quarter valued at $97,000. Finally, Cubist Systematic Strategies LLC increased its stake in enGene by 15.7% during the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after purchasing an additional 2,080 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Trading Up 2.0 %

ENGN traded up $0.12 during trading on Friday, reaching $5.96. 22,766 shares of the stock traded hands, compared to its average volume of 130,217. The stock has a market capitalization of $263.31 million, a PE ratio of -10.27 and a beta of -0.65. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock’s 50-day moving average is $6.74 and its 200 day moving average is $7.15. enGene has a 12 month low of $4.42 and a 12 month high of $18.40.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.06. Equities analysts anticipate that enGene will post -1.56 earnings per share for the current year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.